Related Experiment Video

Updated: Jun 1, 2026

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
10:27

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

Combination of PI3K/mTOR inhibitors: antitumor activity and molecular correlates

Marco Mazzoletti1, Francesca Bortolin, Laura Brunelli

  • 1Laboratory of Molecular Pharmacology and Laboratory of Antitumoral Pharmacology, Department of Oncology, and Gene and Protein Biomarkers Unit, Istituto di Ricerche Farmacologiche Mario Negri, Milan, Italy.

Cancer Research
|May 24, 2011
PubMed

Insights

Combining mTOR inhibitors with PI3K/mTOR inhibitors maximizes pathway inhibition in cancer cells. This dual approach shows enhanced efficacy and sustained Akt inhibition, offering potential therapeutic benefits.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • The phosphatidylinositol-3-kinase (PI3K)/Akt/mTOR pathway is a critical regulator of cell growth and survival, frequently dysregulated in cancer.
  • Targeting this pathway is a key strategy in cancer therapy, but achieving maximal inhibition remains a challenge.

Purpose of the Study:

  • To investigate the efficacy of combining allosteric mTOR inhibitors with a dual PI3K/mTOR kinase inhibitor for enhanced pathway inhibition.
  • To evaluate the molecular mechanisms and therapeutic potential of this combination strategy in cancer models.

Main Methods:

  • In vitro and in vivo studies using human ovarian and prostate cancer cell lines with pathway alterations.
  • Combination therapy with allosteric mTOR inhibitors (rapamycin, RAD001) and a dual PI3K/mTOR inhibitor (PI-103).
  • Molecular analysis including Western blotting for protein phosphorylation and expression, and proteomic analysis to identify key regulators.

Main Results:

  • The combination therapy demonstrated superior activity compared to single agents in inhibiting the PI3K/Akt/mTOR pathway in cancer cells.
  • Combined inhibition prevented Akt rebound activation and sustained Akt phosphorylation, leading to enhanced inhibition of downstream targets like 4EBP1.
  • Proteomic analysis identified c-Myc as a key regulator of downstream protein reduction following combined mTOR inhibition.

Conclusions:

  • Combining catalytic and allosteric mTOR inhibitors offers enhanced therapeutic activity without increased toxicity.
  • This combination strategy holds significant therapeutic implications for effectively inhibiting the PI3K/Akt/mTOR pathway in clinical cancer treatment.

More Related Videos

Exploring the Pharmacological Action and Molecular Mechanism of Salidroside in Inhibiting MCF-7 Cell Proliferation and Migration11:13

Exploring the Pharmacological Action and Molecular Mechanism of Salidroside in Inhibiting MCF-7 Cell Proliferation and Migration

Published on: June 9, 2023

Related Concept Videos

PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a rapamycin-insensitive companion...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...